Cladribine

Key Product Details

Product Description

Cladribine is an adenosine deaminase (ADA)-resistant analog of deoxyadenosine. Exhibits anti-leukemic activity; Inhibits cell growth of lymphoid and myeloid neoplasm (IC₅₀ = 20 - 87 nM). Pro-apoptotic; induces DNA double-strand breaks. Also inhibits ribonuclease reductase (IC₅₀ = 0.11 - 0.28 μM). Displays activity in vitro and in vivo. Orally bioavailable.

Product Specifications for Cladribine

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Cladribine

The following data is based on the product molecular weight 285.69.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.50 mL	17.50 mL	35.00 mL
5 mM	0.70 mL	3.50 mL	7.00 mL
10 mM	0.35 mL	1.75 mL	3.50 mL
50 mM	0.07 mL	0.35 mL	0.70 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Robak Older and new formulations of cladr. Pharmacology and clinical efficacy in hematological malignancies. Recent Pat. Anticancer Drug Discov. 2006 PMID: 18221024
• Seto Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 1985 PMID: 2579098
• Bryson Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993 PMID: 7507037

Product Documents for Cladribine